1 | medications | 10,882 |
2 | nephrotoxins | 8 |
3 | bronchodilatators | 7 |
4 | 'β-blockers | 6 |
5 | mediations | 6 |
6 | hypotensors | 5 |
7 | medication/s | 5 |
8 | self-tests | 5 |
9 | ace-i/arb/statins | 4 |
10 | diet-pills | 3 |
11 | globins | 3 |
12 | pharmacoresponse | 3 |
13 | prostatomegaly | 3 |
14 | purinoceptors | 3 |
15 | renewals | 3 |
16 | temodar | 3 |
17 | biodrug | 2 |
18 | doxorubicin-docetaxel | 2 |
19 | drugs/patient-counseling | 2 |
20 | embryopathies | 2 |
21 | interventional™ | 2 |
22 | m-svgs | 2 |
23 | nanofection | 2 |
24 | nitroheterocyclics | 2 |
25 | opticians | 2 |
26 | partial-responders | 2 |
27 | rexetin | 2 |
28 | rugs | 2 |
29 | types/syndromes | 2 |
30 | veregen | 2 |
31 | zdv/ddc | 2 |
32 | 306,000 | 1 |
33 | 4-methyl-2-hexanamine | 1 |
34 | alone.overall | 1 |
35 | analgesic/antipyretic | 1 |
36 | arterials | 1 |
37 | buproplon | 1 |
38 | chlamydial-bacterial | 1 |
39 | chlamydial-viral | 1 |
40 | cis-4,4'-dimethylaminorex | 1 |
41 | discontinuation/continuation | 1 |
42 | dispensed/year | 1 |
43 | dl-methylphenidate | 1 |
44 | drug-oxybutynin | 1 |
45 | drugs.forty-eight | 1 |
46 | efficacy-if | 1 |
47 | group-but | 1 |
48 | highvs | 1 |
49 | imatinb | 1 |
50 | immunossupression | 1 |
51 | medications.4 | 1 |
52 | mesocarb | 1 |
53 | milliaceum | 1 |
54 | mycoplasmal-bacterial | 1 |
55 | mycoplasmal-viral | 1 |
56 | n-formyl-methionylleucyl-phenylalanine | 1 |
57 | noot | 1 |
58 | patterns/trends | 1 |
59 | pioglitazone.hcl-induced | 1 |
60 | remoxlpride | 1 |
61 | repositionings | 1 |
62 | substance-classes | 1 |
63 | tachyphylaxis® | 1 |
64 | treatment.major | 1 |
65 | tripolidine | 1 |
1 | 'β-blockers | 6 |
2 | 306,000 | 1 |
3 | 4-methyl-2-hexanamine | 1 |
4 | ace-i/arb/statins | 4 |
5 | alone.overall | 1 |
6 | analgesic/antipyretic | 1 |
7 | arterials | 1 |
8 | biodrug | 2 |
9 | bronchodilatators | 7 |
10 | buproplon | 1 |
11 | chlamydial-bacterial | 1 |
12 | chlamydial-viral | 1 |
13 | cis-4,4'-dimethylaminorex | 1 |
14 | diet-pills | 3 |
15 | discontinuation/continuation | 1 |
16 | dispensed/year | 1 |
17 | dl-methylphenidate | 1 |
18 | doxorubicin-docetaxel | 2 |
19 | drug-oxybutynin | 1 |
20 | drugs.forty-eight | 1 |
21 | drugs/patient-counseling | 2 |
22 | efficacy-if | 1 |
23 | embryopathies | 2 |
24 | globins | 3 |
25 | group-but | 1 |
26 | highvs | 1 |
27 | hypotensors | 5 |
28 | imatinb | 1 |
29 | immunossupression | 1 |
30 | interventional™ | 2 |
31 | m-svgs | 2 |
32 | mediations | 6 |
33 | medication/s | 5 |
34 | medications | 10,882 |
35 | medications.4 | 1 |
36 | mesocarb | 1 |
37 | milliaceum | 1 |
38 | mycoplasmal-bacterial | 1 |
39 | mycoplasmal-viral | 1 |
40 | n-formyl-methionylleucyl-phenylalanine | 1 |
41 | nanofection | 2 |
42 | nephrotoxins | 8 |
43 | nitroheterocyclics | 2 |
44 | noot | 1 |
45 | opticians | 2 |
46 | partial-responders | 2 |
47 | patterns/trends | 1 |
48 | pharmacoresponse | 3 |
49 | pioglitazone.hcl-induced | 1 |
50 | prostatomegaly | 3 |
51 | purinoceptors | 3 |
52 | remoxlpride | 1 |
53 | renewals | 3 |
54 | repositionings | 1 |
55 | rexetin | 2 |
56 | rugs | 2 |
57 | self-tests | 5 |
58 | substance-classes | 1 |
59 | tachyphylaxis® | 1 |
60 | temodar | 3 |
61 | treatment.major | 1 |
62 | tripolidine | 1 |
63 | types/syndromes | 2 |
64 | veregen | 2 |
65 | zdv/ddc | 2 |
1 | 306,000 | 1 |
2 | medications.4 | 1 |
3 | imatinb | 1 |
4 | mesocarb | 1 |
5 | zdv/ddc | 2 |
6 | analgesic/antipyretic | 1 |
7 | pioglitazone.hcl-induced | 1 |
8 | remoxlpride | 1 |
9 | tripolidine | 1 |
10 | 4-methyl-2-hexanamine | 1 |
11 | n-formyl-methionylleucyl-phenylalanine | 1 |
12 | pharmacoresponse | 3 |
13 | dl-methylphenidate | 1 |
14 | efficacy-if | 1 |
15 | drugs/patient-counseling | 2 |
16 | biodrug | 2 |
17 | chlamydial-bacterial | 1 |
18 | mycoplasmal-bacterial | 1 |
19 | chlamydial-viral | 1 |
20 | mycoplasmal-viral | 1 |
21 | doxorubicin-docetaxel | 2 |
22 | alone.overall | 1 |
23 | milliaceum | 1 |
24 | veregen | 2 |
25 | drug-oxybutynin | 1 |
26 | rexetin | 2 |
27 | immunossupression | 1 |
28 | discontinuation/continuation | 1 |
29 | nanofection | 2 |
30 | buproplon | 1 |
31 | temodar | 3 |
32 | dispensed/year | 1 |
33 | treatment.major | 1 |
34 | medication/s | 5 |
35 | nitroheterocyclics | 2 |
36 | patterns/trends | 1 |
37 | embryopathies | 2 |
38 | types/syndromes | 2 |
39 | substance-classes | 1 |
40 | repositionings | 1 |
41 | rugs | 2 |
42 | m-svgs | 2 |
43 | arterials | 1 |
44 | renewals | 3 |
45 | diet-pills | 3 |
46 | opticians | 2 |
47 | globins | 3 |
48 | ace-i/arb/statins | 4 |
49 | nephrotoxins | 8 |
50 | medications | 10,882 |
51 | mediations | 6 |
52 | partial-responders | 2 |
53 | 'β-blockers | 6 |
54 | hypotensors | 5 |
55 | bronchodilatators | 7 |
56 | purinoceptors | 3 |
57 | self-tests | 5 |
58 | highvs | 1 |
59 | drugs.forty-eight | 1 |
60 | noot | 1 |
61 | group-but | 1 |
62 | cis-4,4'-dimethylaminorex | 1 |
63 | prostatomegaly | 3 |
64 | interventional™ | 2 |
65 | tachyphylaxis® | 1 |